These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 33161300)

  • 21. The role of neurotransmitters in the development of Parkinson's disease-related psychosis.
    Factor SA; McDonald WM; Goldstein FC
    Eur J Neurol; 2017 Oct; 24(10):1244-1254. PubMed ID: 28758318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of hallucinations and psychosis in Parkinson's disease.
    Eng ML; Welty TE
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychiatric comorbidities in patients with Parkinson disease and psychosis.
    Marsh L; Williams JR; Rocco M; Grill S; Munro C; Dawson TM
    Neurology; 2004 Jul; 63(2):293-300. PubMed ID: 15277623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank.
    Wainberg M; Jacobs GR; di Forti M; Tripathy SJ
    Transl Psychiatry; 2021 Apr; 11(1):211. PubMed ID: 33837184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Psychosis in Parkinson's disease].
    Rongve A; Auning E; Ehrt U; Arsland D
    Tidsskr Nor Laegeforen; 2012 Jan; 132(2):155-8. PubMed ID: 22278271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of psychosis in Parkinson's disease: safety considerations.
    Fernandez HH; Trieschmann ME; Friedman JH
    Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive correlates of hallucinations and delusions in Parkinson's disease.
    Factor SA; Scullin MK; Sollinger AB; Land JO; Wood-Siverio C; Zanders L; Freeman A; Bliwise DL; McDonald WM; Goldstein FC
    J Neurol Sci; 2014 Dec; 347(1-2):316-21. PubMed ID: 25466695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scales to assess psychosis in Parkinson's disease: Critique and recommendations.
    Fernandez HH; Aarsland D; Fénelon G; Friedman JH; Marsh L; Tröster AI; Poewe W; Rascol O; Sampaio C; Stebbins GT; Goetz CG
    Mov Disord; 2008 Mar; 23(4):484-500. PubMed ID: 18175343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease-Results of a multicenter open trial.
    Kashihara K; Maeda T; Yoshida K
    Neuropsychopharmacol Rep; 2022 Jun; 42(2):135-141. PubMed ID: 35226404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson's Disease.
    Pizzolato K; Thacker D; Toro-Pagán ND; Hanna A; Turgeon J; Matos A; Amin N; Michaud V
    Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G; Bernardi S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):311-3. PubMed ID: 16919377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Parkinson's Disease Psychosis.
    Elsibai H; Kualleny M; Fandy TE
    Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841
    [No Abstract]   [Full Text] [Related]  

  • 34. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
    Merims D; Balas M; Peretz C; Shabtai H; Giladi N
    Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real or imagined: We need a new scale for psychosis in Parkinson's disease.
    Pontone GM; Mills KA; Dobkin RD; Hinkle JT; Nirenberg MJ; Schneider RB;
    Parkinsonism Relat Disord; 2024 Apr; 121():106004. PubMed ID: 38278654
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.
    Broadstock M; Ballard C; Corbett A
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):779-86. PubMed ID: 25301532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deconstructing psychosis and misperception symptoms in Parkinson's disease.
    Nishio Y; Yokoi K; Uchiyama M; Mamiya Y; Watanabe H; Gang M; Baba T; Takeda A; Hirayama K; Mori E
    J Neurol Neurosurg Psychiatry; 2017 Sep; 88(9):722-729. PubMed ID: 28600444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Understanding of Psychosis in Parkinson's Disease.
    Ojo OO; Fernandez HH
    Curr Psychiatry Rep; 2016 Oct; 18(10):97. PubMed ID: 27629356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults.
    McGrath J; Welham J; Scott J; Varghese D; Degenhardt L; Hayatbakhsh MR; Alati R; Williams GM; Bor W; Najman JM
    Arch Gen Psychiatry; 2010 May; 67(5):440-7. PubMed ID: 20194820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and impact of mental health issues in Parkinson's disease unplanned hospital admissions.
    Foley JA; Willis C
    Parkinsonism Relat Disord; 2023 Oct; 115():105805. PubMed ID: 37607451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.